Psoriasis drug trial aims to calm overactive immune cells
NCT ID NCT05858645
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how deucravacitinib, a drug that blocks a specific immune signal (TYK2), changes immune cells in the skin and blood of people with moderate-to-severe psoriasis. About 25 adults will take the drug and be monitored for improvements in their psoriasis symptoms. The goal is to understand how the drug works and whether it can reduce disease severity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS VULGARIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an ancient herbal mix tame psoriasis flares?
- Small study to uncover how psoriasis drug tames the immune system
- Diabetes drug cream shows promise for psoriasis in new trial
- Blood test may end guesswork in psoriasis dosing
- New study to measure psoriasis treatment success beyond the skin
- Could a plant cream soothe psoriasis? new trial tests it